236 related articles for article (PubMed ID: 22018195)
1. Low-dose corticosteroids and disease modifying drugs in patients with rheumatoid arthritis.
Malysheva O; Baerwald CG
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S113-5. PubMed ID: 22018195
[TBL] [Abstract][Full Text] [Related]
2. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs.
Malysheva OA; Wahle M; Wagner U; Pierer M; Arnold S; Häntzschel H; Baerwald CG
J Rheumatol; 2008 Jun; 35(6):979-85. PubMed ID: 18412314
[TBL] [Abstract][Full Text] [Related]
3. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis.
Lacaille D; Guh DP; Abrahamowicz M; Anis AH; Esdaile JM
Arthritis Rheum; 2008 Aug; 59(8):1074-81. PubMed ID: 18668604
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoids in rheumatoid arthritis: the silent companion in the therapeutic strategy.
Berardicurti O; Ruscitti P; Pavlych V; Conforti A; Giacomelli R; Cipriani P
Expert Rev Clin Pharmacol; 2020 Jun; 13(6):593-604. PubMed ID: 32434398
[TBL] [Abstract][Full Text] [Related]
5. Better clinical outcome of total knee arthroplasty for rheumatoid arthritis with perioperative glucocorticoids and disease-modifying anti-rheumatic drugs after an average of 11.4-year follow-up.
Ren Y; Yang Q; Luo T; Lin J; Jin J; Qian W; Weng X; Feng B
J Orthop Surg Res; 2021 Jan; 16(1):84. PubMed ID: 33504345
[TBL] [Abstract][Full Text] [Related]
6. Corticosteroids as disease modifying drugs in rheumatoid arthritis treatment.
Yazici Y
Bull NYU Hosp Jt Dis; 2012; 70 Suppl 1():11-3. PubMed ID: 23259652
[TBL] [Abstract][Full Text] [Related]
7. The supplementary therapeutic DMARD role of low-dose glucocorticoids in rheumatoid arthritis.
Cutolo M; Spies CM; Buttgereit F; Paolino S; Pizzorni C
Arthritis Res Ther; 2014 Nov; 16 Suppl 2(Suppl 2):S1. PubMed ID: 25608624
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs.
Sugimori S; Watanabe T; Tabuchi M; Kameda N; Machida H; Okazaki H; Tanigawa T; Yamagami H; Shiba M; Watanabe K; Tominaga K; Fujiwara Y; Oshitani N; Koike T; Higuchi K; Arakawa T
Digestion; 2008; 78(4):208-13. PubMed ID: 19142000
[TBL] [Abstract][Full Text] [Related]
9. The role of low-dose glucocorticoids for rheumatoid arthritis in the biologic era.
Caporali R; Scirè CA; Todoerti M; Montecucco C
Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S9-13. PubMed ID: 24129129
[TBL] [Abstract][Full Text] [Related]
10. Current evidence for the management of rheumatoid arthritis with glucocorticoids: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.
Gorter SL; Bijlsma JW; Cutolo M; Gomez-Reino J; Kouloumas M; Smolen JS; Landewé R
Ann Rheum Dis; 2010 Jun; 69(6):1010-4. PubMed ID: 20448288
[TBL] [Abstract][Full Text] [Related]
11. Update on the use of steroids in rheumatoid arthritis.
García-Magallón B; Silva-Fernández L; Andreu-Sánchez JL
Reumatol Clin; 2013; 9(5):297-302. PubMed ID: 23726772
[TBL] [Abstract][Full Text] [Related]
12. Induction therapy with a combination of DMARDs is better than methotrexate monotherapy: first results of the tREACH trial.
de Jong PH; Hazes JM; Barendregt PJ; Huisman M; van Zeben D; van der Lubbe PA; Gerards AH; de Jager MH; de Sonnaville PB; Grillet BA; Luime JJ; Weel AE
Ann Rheum Dis; 2013 Jan; 72(1):72-8. PubMed ID: 22679301
[TBL] [Abstract][Full Text] [Related]
13. Factors associated with discontinuation of glucocorticoids after starting biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients.
Inoue M; Kanda H; Tateishi S; Fujio K
Mod Rheumatol; 2020 Jan; 30(1):58-63. PubMed ID: 30484724
[No Abstract] [Full Text] [Related]
14. Safety and retention of combination triple disease-modifying anti-rheumatic drugs in new-onset rheumatoid arthritis.
Cummins L; Katikireddi VS; Shankaranarayana S; Su KY; Duggan E; Videm V; Pahau H; Thomas R
Intern Med J; 2015 Dec; 45(12):1266-73. PubMed ID: 26384029
[TBL] [Abstract][Full Text] [Related]
15. [Disease modifying anti-rheumatic drugs(DMARDs)].
Matsuda Y
Nihon Rinsho; 1999 Feb; 57(2):439-44. PubMed ID: 10078020
[TBL] [Abstract][Full Text] [Related]
16. A dose of only 5 mg prednisolone daily retards radiographic progression in early rheumatoid arthritis - the Low-Dose Prednisolone Trial.
Wassenberg S; Rau R; Zeidler H;
Clin Exp Rheumatol; 2011; 29(5 Suppl 68):S68-72. PubMed ID: 22018187
[TBL] [Abstract][Full Text] [Related]
17. Treatment of very early rheumatoid arthritis with symptomatic therapy, disease-modifying antirheumatic drugs, or biologic agents: a cost-effectiveness analysis.
Finckh A; Bansback N; Marra CA; Anis AH; Michaud K; Lubin S; White M; Sizto S; Liang MH
Ann Intern Med; 2009 Nov; 151(9):612-21. PubMed ID: 19884622
[TBL] [Abstract][Full Text] [Related]
18. Patient Preferences for Disease-modifying Antirheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review.
Durand C; Eldoma M; Marshall DA; Bansback N; Hazlewood GS
J Rheumatol; 2020 Feb; 47(2):176-187. PubMed ID: 30988125
[TBL] [Abstract][Full Text] [Related]
19. Glucocorticoid treatment in rheumatoid arthritis.
Rau R
Expert Opin Pharmacother; 2014 Aug; 15(11):1575-83. PubMed ID: 24856989
[TBL] [Abstract][Full Text] [Related]
20. What's new in rheumatoid arthritis? An evidenced based review.
Ostor AJ; McColl GJ
Aust Fam Physician; 2001 Apr; 30(4):314-20. PubMed ID: 11355216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
